Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Friday. Shares of Humana Inc (NYSE: HUM ) rose sharply after the company said Friday that its 2027 Medicare Advantage Star Ratings improved significantly, with 95% of members enrolled in plans earning at least four stars from the Centers for Medicare and Medicaid Services (CMS). Additionally, 42% of its Medicare Advantage members are enrolled in plans rated 4.5 stars or higher, reflecting broad improvements across its portfolio. The company also reaffirmed its FY26 adjusted EPS guidance. Humana shares jumped 12.3% to $434.84 on Friday. Here are some other big stocks recording gains in today’s session. Evolution Metals & Technologies Corp (NASDAQ: EMAT ) shares jumped 13.8% to $1.94 after the company raised its FY26 revenue range. Absci Corp (NASDAQ: ABSI ) surged 13.4% to $10.14. Novavax Inc (NASDAQ: NVAX ) gained 13.3% to $12.47. Ginkgo Bioworks Holdings Inc (NYSE: DNA ) gained 12.4% to $12.74 as the company announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program. Prime Medicine, Inc (NASDAQ: PRME ) gained 12% to $
S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Friday. Shares of Humana Inc (NYSE: HUM ) rose sharply after the company said Friday that its 2027 Medicare Advantage Star Ratings improved significantly, with 95% of members enrolled in plans earning at least four stars from the Centers for Medicare and Medicaid Services (CMS). 5 stars or higher, reflecting broad improvements across its portfolio.
The company also reaffirmed its FY26 adjusted EPS guidance. 84 on Friday. Here are some other big stocks recording gains in today’s session. 94 after the company raised its FY26 revenue range.
14. 47. 74 as the company announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program. 01.
86. 67. 09. 86.
Oppenheimer analyst Param Singh upgraded Fastly from Perform to Outperform and announced a $35 price target. 10. Leerink Partners analyst Lili Nsongo maintained Arcturus Therapeutics with an Outperform rating and raised the price target from $13 to $19. 47.
09. 31 as the company reported preliminary third-quarter production of 95,557 gold equivalent ounces, up 29% year over year. 10. 25.
60. 23. 91. Photo via Shutterstock